Though not statistically significant, HR point estimates indicate lower prostate cancer risk in HHV-8 seropositive men, overall (age-adjusted HR 0.88, 95% CI 0.46-1.69) and in HHV-8 seropositive men with elevated Wave 1 PSA (age-adjusted HR 0.39, 95% CI 0.10-1.63), and equivalent risk in HHV-8 seropositive men with non-elevated Wave 1 PSA (age-adjusted HR 1.03, 95% CI 0.49-2.16). The gene discussed is PROS1; the disease is prostate cancer.